Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CDC25A | P30304 | 1/20 | 0.31 |
| ▸ | CDC25B | P30305 | 1/20 | 0.31 |
| ▸ | CDC25C | P30307 | 1/20 | 0.31 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26501745 | 0.81 | — | — | |
| SCHEMBL26501659 | 0.80 | SLC40A1 (0.34) | MEN1KMT2APOLBRAB9AMAPK1 | |
| SCHEMBL26501684 | 0.77 | SLC40A1 (0.36) | MEN1KMT2APOLBRAB9AMAPK1 | |
| SCHEMBL26501719 | 0.74 | KDM4E (0.33) | — | |
| SCHEMBL26501718 | 0.73 | PANK3 (0.35) | MEN1KMT2A | |
| SCHEMBL12894439 | 0.73 | CDK5 (0.40) | MEN1KMT2APOLBRAB9AMAPK1 | |
| SCHEMBL26501709 | 0.71 | BCHE (0.38) | MEN1KMT2APOLBRAB9A | |
| SCHEMBL26501801 | 0.70 | POLB (0.33) | POLBRAB9ASLC40A1 | |
| SCHEMBL26501744 | 0.68 | ALDH1A1 (0.32) | — | |
| SCHEMBL26501704 | 0.68 | RAB9A (0.45) | MEN1KMT2APOLBRAB9AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321092-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321092-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | HMGCR, GCDH, CYP11A1 | MEN1 2263/4885KMT2A 1296/4885POLB 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.